GLP-1s won't end sugar reduction
US$ 26.30
companies developing glp-1 drugs Chinese Are Advanced GLP-1 Receptor Agonist Companies and
Description
The tendency to fluid retention is highly prevalent in diabetic kidney disease 34
Onceweekly dulaglutide versus oncedaily liraglutide in metformintreated patients with type 2 diabetes (AWARD6): a randomised, openlabel, phase 3, noninferiority trial
Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, et al
The vasodilatory effects were not observed after denuding the endothelium from the rat coronary arteries, thus suggesting endothelium-dependent effects (Xiong et al., 2019)
doi:10.1016/j.neuroscience.2012.09.025 76
Its important to speak to your healthcare provider about any concerns or adverse reactions while using Saxenda
